MRCPsychLog in

Topics

Paper APaper B

Paper A · Clinical Psychopharmacology

All topics
  • Switching antidepressantsClinical Psychopharmacology
  • Anti-dementia drug mechanisms (cholinesterase inhibitors and memantine)Clinical Psychopharmacology
  • Pharmacodynamic termsClinical Psychopharmacology
  • Antidepressants in pregnancyClinical Psychopharmacology
  • Lithium teratogenicityClinical Psychopharmacology
  • Lithium toxicity and monitoringClinical Psychopharmacology
  • Substance pharmacology (stimulants)Clinical Psychopharmacology
  • Teratogenicity in pregnancyClinical Psychopharmacology
  • Drug half-livesClinical Psychopharmacology
  • Prodrugs and active metabolitesClinical Psychopharmacology
  • Transcranial magnetic stimulation (TMS)Clinical Psychopharmacology
  • Pregabalin and gabapentinClinical Psychopharmacology
  • Tolerance and cross-toleranceClinical Psychopharmacology
  • Congenital malformations associated with valproate in pregnancyClinical Psychopharmacology
  • MAOI dietary interactions (tyramine)Clinical Psychopharmacology
  • Therapeutic drug monitoringClinical Psychopharmacology
  • ECT mechanism of actionClinical Psychopharmacology
Eating disorder epidemiologyClinical Psychopharmacology
  • Orexin receptor antagonistsClinical Psychopharmacology
  • Vagus nerve stimulation (VNS)Clinical Psychopharmacology
  • Antipsychotic hyperprolactinaemiaClinical Psychopharmacology
  • Tardive dyskinesiaClinical Psychopharmacology
  • Hyperprolactinaemia managementClinical Psychopharmacology
  • FlumazenilClinical Psychopharmacology
  • Antipsychotic-induced metabolic syndromeClinical Psychopharmacology
  • Plasma protein bindingClinical Psychopharmacology
  • Alcohol pharmacokineticsClinical Psychopharmacology
  • Alpha-1 antagonism effectsClinical Psychopharmacology
  • Neuroleptic malignant syndromeClinical Psychopharmacology
  • Clozapine safetyClinical Psychopharmacology
  • Clonidine and alpha-2 adrenergic agonistsClinical Psychopharmacology
  • Neurosurgery for mental disorder (psychosurgery)Clinical Psychopharmacology
  • Psychotropic drug interactions (warfarin, St John's wort)Clinical Psychopharmacology
  • Electroconvulsive therapy (ECT)Clinical Psychopharmacology
  • Serotonin syndrome versus NMSClinical Psychopharmacology
  • Melatonin and ramelteonClinical Psychopharmacology
  • Antipsychotic receptor pharmacologyClinical Psychopharmacology
  • Z-drugs / GABAClinical Psychopharmacology
  • Clozapine seizure riskClinical Psychopharmacology
  • Anticonvulsant mood stabilisers (valproate / carbamazepine / lamotrigine)Clinical Psychopharmacology
  • Aripiprazole partial D2 agonismClinical Psychopharmacology
  • Drug mechanisms (MOA)Clinical Psychopharmacology
  • Lithium side effectsClinical Psychopharmacology
  • Disulfiram reactionClinical Psychopharmacology
  • Glutamate modulators (NMDA)Clinical Psychopharmacology
  • Beta-blockers in psychiatryClinical Psychopharmacology
  • Acetylator status and metabolismClinical Psychopharmacology
  • Serotonin syndromeClinical Psychopharmacology
  • BuspironeClinical Psychopharmacology
  • Agomelatine mechanismClinical Psychopharmacology
  • Naltrexone and acamprosateClinical Psychopharmacology
  • Postural (orthostatic) hypotension: definition and criteriaClinical Psychopharmacology
  • Pharmacokinetic order (first-order vs steady state)Clinical Psychopharmacology
  • Seizure threshold and drugsClinical Psychopharmacology
  • Newer antipsychotic mechanisms (cariprazine, lurasidone, brexpiprazole)Clinical Psychopharmacology
  • Smoking and drug metabolismClinical Psychopharmacology
  • Pellagra (niacin/B3 deficiency)Clinical Psychopharmacology
  • Drug selection (clinical)Clinical Psychopharmacology
  • Zero-order kineticsClinical Psychopharmacology
  • Mood stabilisers in pregnancyClinical Psychopharmacology
  • Bupropion mechanismClinical Psychopharmacology
  • Antidepressant mechanismsClinical Psychopharmacology
  • Area under the curveClinical Psychopharmacology
  • AmantadineClinical Psychopharmacology
  • Depot antipsychotic kineticsClinical Psychopharmacology
  • Sildenafil mechanismClinical Psychopharmacology
  • CATIE trialClinical Psychopharmacology
  • Atypical antipsychotic receptor profileClinical Psychopharmacology
  • Herbal psychotropics: St John's Wort and KavaClinical Psychopharmacology
  • Light therapy for seasonal affective disorderClinical Psychopharmacology
  • Ketamine and esketamineClinical Psychopharmacology
  • Safe sedatives in hepatic impairment (LOT rule)Clinical Psychopharmacology
  • SSRI bleeding riskClinical Psychopharmacology
  • Varenicline (nicotinic partial agonist)Clinical Psychopharmacology
  • Antidepressant discontinuationClinical Psychopharmacology
  • Benzodiazepine mechanismClinical Psychopharmacology
  • Beta-blocker contraindicationsClinical Psychopharmacology
  • Mood stabiliser choice in renal impairmentClinical Psychopharmacology
  • Extrapyramidal side effects (acute dystonia and drug-induced parkinsonism)Clinical Psychopharmacology
  • Antipsychotic chemical classesClinical Psychopharmacology
  • ADHD pharmacologyClinical Psychopharmacology
  • Opioid pharmacologyClinical Psychopharmacology
  • Drug interactions (cytochrome P450)Clinical Psychopharmacology
  • Drug-specific side effectsClinical Psychopharmacology
  • Lithium interactions and toxicity triggersClinical Psychopharmacology
  • AkathisiaClinical Psychopharmacology
  • QTc prolongation with psychotropicsClinical Psychopharmacology
  • QT prolongation from drug interactionsClinical Psychopharmacology
  • Deep brain stimulation (DBS)Clinical Psychopharmacology